Synapse

← Cancer Drug Resistance

Papers in Cancer Drug Resistance

Page 7 · newest first

  1. SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistanceCancer Drug Resistance · 2021
  2. Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancerCancer Drug Resistance · 2021
  3. Emerging RAS-directed therapies for cancerCancer Drug Resistance · 2021
  4. The aqueous extract of brucea javanica reduces tumorigenicity of human lung cancer tumorspheresCancer Drug Resistance · 2021
  5. Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancerCancer Drug Resistance · 2021
  6. MYC inhibitors in multiple myelomaCancer Drug Resistance · 2021
  7. Statins and endocrine resistance in breast cancerCancer Drug Resistance · 2021
  8. The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistanceCancer Drug Resistance · 2021
  9. Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancerCancer Drug Resistance · 2021
  10. Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinicsCancer Drug Resistance · 2021
  11. P53-regulated autophagy and its impact on drug resistance and cell fateCancer Drug Resistance · 2021
  12. UCP2 - Taking the heat out of P-glycoprotein?Cancer Drug Resistance · 2021
  13. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a reviewCancer Drug Resistance · 2021
  14. Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cellsCancer Drug Resistance · 2020
  15. Gene silencing of HIF-2α disrupts glioblastoma stem cell phenotypeCancer Drug Resistance · 2020
  16. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewCancer Drug Resistance · 2020
  17. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistanceCancer Drug Resistance · 2020
  18. RET kinase alterations in targeted cancer therapyCancer Drug Resistance · 2020
  19. https://cdrjournal.com/article/view/3531Cancer Drug Resistance · 2020
  20. Resistance to venetoclax and hypomethylating agents in acute myeloid leukemiaCancer Drug Resistance · 2020
  21. The dark side of immunotherapy: pancreatic cancerCancer Drug Resistance · 2020
  22. Key genes and drug delivery systems to improve the efficiency of chemotherapyCancer Drug Resistance · 2020
  23. Manipulation of the immune system by non-small cell lung cancer and possible therapeutic interferenceCancer Drug Resistance · 2020
  24. Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activatorsCancer Drug Resistance · 2020
  25. Imaging probes for non-invasive tumoral detection and functional monitoring of cancer multidrug resistanceCancer Drug Resistance · 2020
  26. Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problemCancer Drug Resistance · 2020
  27. Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemiaCancer Drug Resistance · 2020
  28. Nitric oxide-elicited resistance to anti-glioblastoma photodynamic therapyCancer Drug Resistance · 2020
  29. MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancerCancer Drug Resistance · 2020
  30. Microfluidic chip enables single-cell measurement for multidrug resistance in triple-negative breast cancer cellsCancer Drug Resistance · 2020
  31. The role of cell free DNA and liquid biopsies in haematological conditionsCancer Drug Resistance · 2020
  32. Why nanodiamond carriers manage to overcome drug resistance in cancerCancer Drug Resistance · 2020
  33. PHGDH as a mechanism for resistance in metabolically-driven cancersCancer Drug Resistance · 2020
  34. Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?Cancer Drug Resistance · 2020
  35. Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistanceCancer Drug Resistance · 2020
  36. Radiotherapy and the cellular DNA damage response: current and future perspectives on head and neck cancer treatmentCancer Drug Resistance · 2020
  37. Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsCancer Drug Resistance · 2020
  38. Decoding cancer’s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockadeCancer Drug Resistance · 2020
  39. Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapyCancer Drug Resistance · 2020
  40. Promises and pitfalls of targeted agents in chronic lymphocytic leukemiaCancer Drug Resistance · 2020
  41. Circulating tumor cells and drug history in primary breast cancer patientsCancer Drug Resistance · 2020
  42. Reversal of doxorubicin resistance in lung cancer cells by neferine is explained by nuclear factor erythroid-derived 2-like 2 mediated lung resistance protein down regulationCancer Drug Resistance · 2020
  43. Cyclin-dependent kinase inhibitors in brain cancer: current state and future directionsCancer Drug Resistance · 2020
  44. Gut microbiota: a new player in regulating immune- and chemo-therapy efficacyCancer Drug Resistance · 2020
  45. Pretreatment inflammatory indices predict Bevacizumab response in recurrent GliomaCancer Drug Resistance · 2020
  46. The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomasCancer Drug Resistance · 2020
  47. The interplay between DNA topoisomerase 2α post-translational modifications and drug resistanceCancer Drug Resistance · 2020
  48. Resistance to chemoimmunotherapy in non-small-cell lung cancerCancer Drug Resistance · 2020
  49. Identification of sequence-specific interactions of the CD44-intracellular domain with RUNX2 in the transcription of matrix metalloprotease-9 in human prostate cancer cellsCancer Drug Resistance · 2020
  50. A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myelomaCancer Drug Resistance · 2020